Eli Lilly's (LLY) Fundamentals and Pipeline are Encouraging, Continue to Support Positive View - BMO Capital Markets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Eli Lilly (LLY) PT Lowered to $305 at BMO Capital
February 4, 2022 6:55 AM ESTBMO Capital analyst Evan David Seigerman lowered the price target on Eli Lilly (NYSE: LLY) to $305.00 (from $310.00) while maintaining an Outperform rating.
The analyst commented, "Donanemab concerns overshadow a solid quarter and set up into 2022. Despite solid set of 4Q21 results and reiterated... More
Eli Lilly's (LLY) Earnings Outlook Continues to Look Favorable VS Peers, Reiterate Overweight - Cantor Fitzgerald
February 3, 2022 7:13 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $335.00 price target on Eli Lilly (NYSE: LLY), following the company's Q4 earnings report.
The analyst quotes: "Post a 4Q21 sales (beat versus FactSet for Trulicity, Taltz, Jardiance and Verzenio, among other... More
Eli Lilly pushes back timeline for Alzheimer's drug application
February 3, 2022 6:35 AM ESTBy Leroy Leo
(Reuters) - Eli Lilly and Co deferred its timeline to complete application for accelerated approval of its experimental Alzheimer's drug, saying it expects such an approval to make little difference with Medicare's limited coverage terms.
Shares of Eli Lilly fell 2.6% to $244.21 on Thursday, after the drugmaker said it would complete the application sometime later in 2022, pushing away from first quarter, its initial timeline.
The U.S. Centers for Medicaid and Medicare Services... More
Eli Lilly & Co. (LLY) Tops Q4 EPS by 34c, Revenue Beats, Offers Guidance
February 3, 2022 6:26 AM ESTEli Lilly & Co. (NYSE: LLY) reported Q4 EPS of $2.49, $0.34 better than the analyst estimate of $2.15. Revenue for the quarter came in at $8 billion versus the consensus estimate of $6.74 billion.
GUIDANCE:
Eli Lilly & Co. sees FY2022 EPS of $8.50-$8.65, versus the... More
